| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 11 | 77.9x | 17.8x | Bottom tier | |
Growth | 84 | 17.6% | 7.1% | Top tier | |
Quality | 79 | 7.9% | 4.5% | Top tier | |
Safety | 93 | — | 2.6x | Top tier | |
Capital Return | 69 | — | 2.12% | Top tier | |
Momentum | 56 | 19.1% | 2.9% | Around median | |
Sentiment | 81 | 9 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Penumbra generates revenue from vascular intervention technologies, and its reported business is divided between thrombectomy and embolization and vascular access. Its thrombectomy portfolio growth drivers include CAVT technology and Lightning and Bolt products, while its embolization portfolio includes Ruby XL and Swift products; in Q3 FY2025, thrombectomy represented $236.4 million, or approximately 66.6% of revenue, compared with $118.3 million for embolization and vascular access, or approximately 33.4%.
In Q2 FY2026, revenue was $390.0 million, gross profit was $264.9 million, net income was $34.8 million, and earnings per share were $0.88. These results equate to a gross margin of approximately 67.9% and a net income margin of approximately 8.9%, compared with revenue of $374.8 million and net income of $32.6 million in Q1 FY2026.
For the twelve months ended in FY2026, according to the latest EDGAR data, Penumbra recorded revenue of $1.5 billion, gross profit of $1.0 billion, net income of $160.6 million, and earnings per share of approximately $4.06. For the full FY2025, it recorded revenue of $1.4 billion and net income of $177.7 million, showing that revenue growth was not accompanied by a comparable increase in net income in the latest trailing period.
The analyst consensus is “Neutral,” with an average price target of $320 and identical high and low targets of $320, meaning the range is based on a single estimate or identical estimates and does not provide meaningful dispersion of views. This target is below the 52-week high of $362.41 and above the low of $221.26, while the available data do not include a published price-to-earnings multiple that could be used to assess valuation relative to earnings.
Figures in the text are as of 2026-08-29; the live price is shown at the top of the page.
Reported revenue is divided primarily between thrombectomy and embolization and vascular access. In Q3 FY2025, thrombectomy generated $236.4 million, compared with $118.3 million for embolization and vascular access. The products and technologies mentioned include CAVT, Lightning, Bolt, Ruby XL, and Swift.
In Q2 FY2026, revenue was $390.0 million and gross profit was $264.9 million. Net income was $34.8 million and earnings per share were $0.88, with a gross margin of approximately 67.9%. For the twelve months ended in FY2026, according to the latest filing, revenue was $1.5 billion and net income was $160.6 million.
STORM-PE compared CAVT with anticoagulation against anticoagulation alone in patients with intermediate- to high-risk acute pulmonary embolism. The study showed CAVT's superiority in reducing right-heart strain, with a comparable safety profile and multiple secondary outcomes favoring the technology. After the results were presented at TCT and VIVA during 2025, management said hospitals and physicians had begun working to update treatment protocols, but broader adoption will take time.
Automated analysis for informational purposes only — not investment advice.
Penumbra stated on the November 5, 2025 call that Thunderbolt is a new product undergoing 510(k) review, not a cleared product seeking an expansion of an existing use. In October 2025, the company submitted comprehensive responses to the questions it had received from the FDA and then entered the stage of addressing any final questions or clarifications. The company did not announce a confirmed clearance or launch date in the text, so a specific financial contribution from the product cannot be included.
Gross margin increased to 67.8% in Q3 FY2025, up 130 basis points year over year and 180 basis points sequentially. Non-GAAP operating income was approximately $48.8 million, or 13.8% of revenue, compared with 13.4% in the comparable period. Management is targeting a gross margin above 70% by the end of 2026, but operating expenses represented 54% of Q3 FY2025 revenue after the expansion of sales teams.
The United States represented 77.5% of Q3 FY2025 sales, increasing the sensitivity of results to trends in that market. The U.S. stroke market experienced a slight decline and pressured thrombectomy growth, while China remained an obstacle to international growth. Additional risks include the incomplete FDA review of Thunderbolt and the increase in selling, general, and administrative expenses to $168.9 million in that quarter.
